Results 61 to 70 of about 27,568 (254)

Effect of Streptokinase on Hemostasis [PDF]

open access: yesBlood, 1968
Abstract The effect of streptokinase on hemostasis was studied by direct observation of hemostatic plugs in the rabbit mesentery. Infusion of streptokinase did not produce dissolution of hemostatic plugs which were already formed. It did cause a delay in the formation of a platelet mass capable of arresting bleeding from injured vessels.
J F Mustard   +5 more
openaire   +3 more sources

Hydrophobic residues in the D‐domain of a plasminogen‐binding M‐protein modulate α‐helicity, oligomerization, and surface anchoring in Streptococcus pyogenes

open access: yesProtein Science, Volume 34, Issue 10, October 2025.
Abstract Human plasminogen (hPg) binding M‐protein (PAM) is a major virulence determinant of Group A Streptococcus (GAS). PAM contains irregularly spaced heptad repeats, particularly within its C‐ and D‐domains. Our recent cryo‐EM structure of PAM from GAS strain AP53 (PAMAP53) revealed that these repeats do not favor coiled‐coil formation, but instead
Olawole Ayinuola   +3 more
wiley   +1 more source

Fermentation, fractionation and purification of streptokinase by chemical reduction method

open access: yesIranian Journal of Microbiology, 2011
Background and Objectives: Streptokinase is used clinically as an intravenous thrombolytic agent for the treatment of acute myocardial infarction and is commonly prepared from cultures of Streptococcus equisimilis strain H46A.
Z Karimi   +4 more
doaj  

Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency: The GUSTO Enzyme Substudy [PDF]

open access: yes, 2017
Background The recent international GUSTO trial of 41 021 patients with acute myocardial infarction demonstrated improved 90-mm infarct related artery patency as well as reduced mortality in patients treated with an accelerated regimen of tissue ...
Baardman, T.   +6 more
core  

Group A Streptococcus interacts with glycosaminoglycans via M proteins to modulate bacterial adherence in vitro

open access: yesThe FEBS Journal, Volume 292, Issue 20, Page 5540-5562, October 2025.
Interactions between bacteria and the extracellular matrix are a prerequisite for colonisation and infection. Phylogenetically diverse M proteins of group A Streptococcus (GAS) can selectively bind sulfated glycosaminoglycans with high affinity. M protein‐mediated recruitment of chondroitin sulfate and dermatan sulfate was shown to increase GAS ...
Tahnee B.‐D. McEwan   +8 more
wiley   +1 more source

The Effect of Recombinant Tissue Plasminogen Activator (r-tPA) on Quantitation of Neutralising Anti-Streptokinase Antibodies

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2004
The measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen.
Afshin Afshari R. Elizbeth Holme
doaj  

The Economics of Healthcare Rationing [PDF]

open access: yes, 2017
This article examines the economics of healthcare rationing. We begin with an overview of the various dimensions across which healthcare rationing operates, or at least has the potential to operate, in the first place.
Frakes, Michael D.   +2 more
core   +1 more source

Tissue plasminogen activator dose and pulmonary artery pressure reduction in catheter directed thrombolysis of submassive pulmonary embolism. [PDF]

open access: yes, 2019
PURPOSE:The purpose of this study is to assess the incremental effect of tissue plasminogen activator (t-PA) dose on pulmonary artery pressure (PAP) and bleeding during catheter directed thrombolysis (CDT) of submassive pulmonary embolism (PE). MATERIALS
Gaba, Ron C   +3 more
core   +2 more sources

Cerebral Venous Thrombosis:Current Status and Challenges

open access: yesBrain and Behavior, Volume 15, Issue 9, September 2025.
Our review introduces treatment strategies for short‐term, long‐term, and permanent CVT risk factors, focusing on anticoagulant selection and treatment duration. We also discuss the current status of endovascular therapy for CVT, noting that it remains a challenge due to limited evidence, and more research is needed to optimize this approach.
Wenbo Zuo   +5 more
wiley   +1 more source

Evaluation of In vivo Bioactivity of a Mutated Streptokinase

open access: yesNovelty in Biomedicine, 2017
 Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of streptokinase is worthy. Recently, we
Marzieh Sameni   +6 more
doaj  

Home - About - Disclaimer - Privacy